EGFR and neoplasm: Therefore, treatment selection mostly has to rely on results from other tumor entities, e.g. breast cancer for DNA damage repair alterations, cholangiocarcinoma and urothelial carcinoma for FGFR alterations, and NSCLC for EGFR alterations [5].